2-(3,7-Dimethyl-octa-2, 6-dienyl)-6-ethylamino-3-hydroxy-5-pentyl-[1,4]benzoquinone

Table of contents


On 9 January 2020, orphan designation EU/3/19/2237 was granted by the European Commission to Emerald Health Pharmaceuticals Espana S.L, Spain, for 2-(3,7-dimethyl-octa-2, 6-dienyl)-6-ethylamino-3-hydroxy-5-pentyl-[1,4]benzoquinone (also known as VCE-003.2) for the treatment of Huntington's disease.

Key facts

Active substance
2-(3,7-Dimethyl-octa-2, 6-dienyl)-6-ethylamino-3-hydroxy-5-pentyl-[1,4]benzoquinone
Intented use
Treatment of Huntington's disease
Date of designation
Orphan designation status
EU designation number

Sponsor's contact details

Emerald Health Pharmaceuticals Espana S.L.
Parque Científico Tecnológico de Córdoba (Rabanales 21)
C/ Astrónoma Cecilia Payne
Edificio Centauro
14014 Córdoba
Tel. + 34 6107 86932

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating